NH TherAguix
Created in 2015
- BETA
Up & running (A)
Existing signals show a regular activity Social networks
1,615Activities
Technologies
Entity types
Location
29 Chem. du Vieux Chêne, 38240 Meylan, France
Meylan
France
Employees
Scale: 11-50
Estimated: 21
Engaged corporates
8
7 1Added in Motherbase
10 months, 3 weeks ago
deeptech Value proposition
Nanomedicine For Precision Radiotherapy
NH TherAguix , a Phase 2 biotech company, has developed an innovative nano drug AGuIX® to improve cancer treatment by radiotherapy to treat tumours and metastases.
Its pharmacological properties and its mode of action by bio-distribution allow it to act in the heart of tumors and confer it a pan-cancer potential.
AGuIX® is currently assessed in 4 Phase II randomized trials in brain metastases using either whole brain radiation therapy (NANORAD2, CHUGA, Grenoble, France) or stereo-radiosurgery (NANOBRAINMETS, Dana Farber Brigham Cancer Center, Boston, USA), in glioblastoma (NANOGBM, multicentric, Clermont Ferrand, France) as well as in pancreatic and lung cancers (NANOSMART, Dana Farber Brigham Cancer Center, Boston, USA).
NH TherAguix was established in 2015 after 10 years of academic research that led to the invention of AGuIX® and the discovery of its radioenhancement effect. Altogether, NH TherAguix raised around €40M of dilutive and non-dilutive funds, including a €13M A series in 2019, led by Bpifrance with Arbevel, Omnes and Supernova.
oncology, nanomedicine, radiotherapy, and theranosticOriginal language
Nanomedicine For Precision Radiotherapy
NH TherAguix , a Phase 2 biotech company, has developed an innovative nano drug AGuIX® to improve cancer treatment by radiotherapy to treat tumours and metastases.
Its pharmacological properties and its mode of action by bio-distribution allow it to act in the heart of tumors and confer it a pan-cancer potential.
AGuIX® is currently assessed in 4 Phase II randomized trials in brain metastases using either whole brain radiation therapy (NANORAD2, CHUGA, Grenoble, France) or stereo-radiosurgery (NANOBRAINMETS, Dana Farber Brigham Cancer Center, Boston, USA), in glioblastoma (NANOGBM, multicentric, Clermont Ferrand, France) as well as in pancreatic and lung cancers (NANOSMART, Dana Farber Brigham Cancer Center, Boston, USA).
NH TherAguix was established in 2015 after 10 years of academic research that led to the invention of AGuIX® and the discovery of its radioenhancement effect. Altogether, NH TherAguix raised around €40M of dilutive and non-dilutive funds, including a €13M A series in 2019, led by Bpifrance with Arbevel, Omnes and Supernova.
Nanomedicine technology for precision radiotherapy - NHT
Nanomedicine technology is an innovative therapeutic approach that has the potential to improve conventional radiotherapy treatment.
https://nhtheraguix.com/
| Corporate | Type | Tweets | Articles | |
|---|---|---|---|---|
 | Invest In Grenoble Alpes | Other 2 May 2024 | | |
 Gustave Roussy Health, Hospitals and Health Care | Gustave Roussy Health, Hospitals and Health Care | Other 6 Jul 2024 | | |
 PULSALYS Research, Research Services | PULSALYS Research, Research Services | Other 6 Feb 2024 | | |
 Linksium Venture Capital and Private Equity Principals | Linksium Venture Capital and Private Equity Principals | Other 3 Feb 2024 | | |
 MEDICALPS Business Consulting and Services | MEDICALPS Business Consulting and Services | Other 19 Jul 2024 | | |
 inovallée, Grenoble Alpes Technopole NGO, Think Tank, Business Consulting and Services | inovallée, Grenoble Alpes Technopole NGO, Think Tank, Business Consulting and Services | Other 12 Oct 2024 | | |
 CNRS Innovation Research, Research Services | CNRS Innovation Research, Research Services | Other 29 Jun 2023 | | |
 Lyonbiopôle Auvergne-Rhône-Alpes Public business cluster, Biotechnology, French Cluster, Biotechnology Research | Lyonbiopôle Auvergne-Rhône-Alpes Public business cluster, Biotechnology, French Cluster, Biotechnology Research | Other 5 Sep 2024 | | |